Advanced Therapeutics Pharmaceutical Outsourcing Global Market Report 2024

The advanced therapeutics pharmaceutical outsourcing market size has grown strongly in recent years. It will grow from $7.64 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%.The growth observed in the historical period can be attributed to several factors, including the expansion of biopharmaceutical infrastructure, adherence to regulatory compliance, a heightened demand for novel drugs addressing chronic and life-threatening diseases, improved operational efficiency, and an increasing demand for personalized medicine.

The advanced therapeutics pharmaceutical outsourcing market size is expected to see steady growth in the next few years. It will grow to $9.76 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing adoption of cell and gene therapies, a growing focus on mRNA therapies, rising demand for cutting-edge treatments, improved efficiency, and cost-effective solutions offered by outsourcing partners, as well as collaborative innovation. Noteworthy trends expected in the forecast period encompass technological advancements, an elevated expertise in advanced therapeutics, a burgeoning pipeline of innovative therapies, the integration of cutting-edge technology, and rapid advancements in gene therapy, cell therapy, and mRNA technologies.

The anticipated increase in the adoption of cell and gene therapies is set to drive the expansion of the advanced therapeutics pharmaceutical outsourcing market in the coming years. Cell and gene therapies, representing innovative treatments that leverage living cells or genetic material to address and cure diseases, have gained prominence in the medical landscape. Advanced therapeutics pharmaceutical outsourcing plays a crucial role in supporting cell and gene therapies by granting access to established providers with a proven track record and experienced personnel. This strategic approach allows companies to save both time and resources that would otherwise be spent on building in-house teams. Notably, a report by Nature, a UK-based scientific journal, projected a significant rise in the number of new patients treated with gene therapies, from 16,244 in 2020 to an estimated 94,696 in 2025, further affirming the driving force behind the growth of the advanced therapeutics pharmaceutical outsourcing market.

Prominent companies in the advanced therapeutics pharmaceutical outsourcing market are actively pursuing strategic partnerships to enhance their service offerings and cater to the needs of their customers effectively. A strategic partnership, characterized by a collaborative arrangement between two or more entities, typically businesses, aims to achieve mutually beneficial goals that may be challenging for each partner to accomplish independently. For instance, in January 2023, Lonza, a Switzerland-based manufacturing company serving the pharmaceutical, biotechnology, and nutrition sectors, entered into a partnership with Context Therapeutics Inc., a US-based biopharmaceutical company specializing in advancing medicines for solid tumors. This collaboration involves Lonza providing key services such as manufacturability assessment, gene and cell line construction, and process development for both drug substance and drug product in support of Context Therapeutics' initiatives.

In August 2022, Catalent Inc., a pharmaceutical company headquartered in the United States, completed the acquisition of Metrics Contract Services and Contract Development and Manufacturing Organization (CDMO) for a total of $475 million. This strategic acquisition is poised to enhance Catalent's expertise in integrated oral solid formulation development, manufacturing, and packaging, thereby enabling customers to streamline and expedite their programs. Additionally, the acquisition will broaden Catalent's capacity to manage highly potent compounds. Metrics Contract Services and Contract Development and Manufacturing Organization (CDMO), a US-based provider offering specialized services for drug development and manufacturing, was identified as a key asset to reinforce Catalent's position in the pharmaceutical industry.

Major companies operating in the advanced therapeutics pharmaceutical outsourcing market report are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, IQVIA, ICON plc, SGS SA, Lonza Group, Parexel International Corporation, WuXi AppTec, Syneos Health, Catalent Inc., Charles River Laboratories International, Recipharm AB, Croda International Plc, Samsung Biologics, Vetter Pharma International GmbH, Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies, Marken, AGC Biologics, Evotec SE, ProPharma Group, Piramal Pharma Solutions, Corden Pharma International LLC, Novotech Pty Ltd., Cryoport Systems Inc., Cytovance Biologics.

North America was the largest region in the advanced therapeutics pharmaceutical outsourcing market in 2023. The regions covered in the advanced therapeutics pharmaceutical outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced therapeutics pharmaceutical outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Advanced Therapeutic Pharmaceutical Outsourcing involves the delegation of specialized pharmaceutical services related to advanced therapeutic products. These products typically encompass advanced therapies such as cell and gene therapies, personalized medicines, biologics, and other innovative treatments. The outsourcing of these services is undertaken to leverage specialized expertise and capabilities in the production, testing, and development of advanced therapeutic products.

The primary services within advanced therapeutics pharmaceutical outsourcing include Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs). CROs and CDMOs offer a range of specialized services to support the development and commercialization of advanced therapeutic products. These services cater to various medical fields, including oncology, neurology, cardiology, infectious diseases, and others. Outsourcing activities may involve services related to cell therapy, gene therapy, and RNA-based therapies, covering preclinical services, clinical services, as well as commercial manufacturing and packaging applications.

The advanced therapeutics pharmaceutical outsourcing market research report is one of a series of new reports that provides advanced therapeutics pharmaceutical outsourcing market statistics, including advanced therapeutics pharmaceutical outsourcing industry global market size, regional shares, competitors with an advanced therapeutics pharmaceutical outsourcing market share, detailed advanced therapeutics pharmaceutical outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the advanced therapeutics pharmaceutical outsourcing industry. This advanced therapeutics pharmaceutical outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The advanced therapeutics pharmaceutical outsourcing market includes revenues earned by entities by providing services such as research and development support, process development and manufacturing, comprehensive analytical testing and characterization, regulatory support, clinical manufacturing, commercial manufacturing, implementation of quality systems, consulting and strategic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.